Literature DB >> 12378169

A medium-term follow-up study of 44 Souter-Strathclyde elbow arthroplasties carried out for rheumatoid arthritis.

Jeremy N Dainton1, Philip M Hutchins.   

Abstract

The results of 44 primary Souter-Strathclyde total elbow arthroplasties performed on 36 patients with rheumatoid arthritis are reported, with a mean follow-up of 6 years (range, 17 months-12 years; median, 6 years). Of these patients, 63% reported complete freedom from pain in the elbow, 25% mild intermittent pain, and 12% moderate pain. The mean range of motion at follow-up was 97 degrees (range, 40 degrees -135 degrees ). This represented a mean gain of 16.5 degrees of flexion, but only a 1.5 degrees gain in extension. Twenty-sevenelbows had a range of motion of 100 degrees or greater compared with 13 before surgery. There was 1 permanent ulnar nerve palsy and 1 deep infection requiring debridement. Six cases (4%) required revision, 2 for olecranon fractures and 4 for loosening. In patients with rheumatoid arthritis with low functional demand, the Souter-Strathclyde total elbow arthroplasty performs well in abolishing pain and increasing independence in carrying out the activities of daily living.

Entities:  

Mesh:

Year:  2002        PMID: 12378169     DOI: 10.1067/mse.2002.124528

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  3 in total

1.  [Comparison of rheumatic and post-traumatic elbow joints after total elbow arthroplasty. Comprehensive and specific evaluation of clinical picture, function, and quality of life].

Authors:  F Angst; J Goldhahn; M John; D B Herren; B R Simmen
Journal:  Orthopade       Date:  2005-08       Impact factor: 1.087

Review 2.  [Dislocation after total elbow arthroplasty].

Authors:  M John; K Schenk; S Lieske; H W Neumann
Journal:  Orthopade       Date:  2007-10       Impact factor: 1.087

Review 3.  Systematic review of primary total elbow prostheses used for the rheumatoid elbow.

Authors:  J C T van der Lugt; P M Rozing
Journal:  Clin Rheumatol       Date:  2004-04-16       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.